Thrombin, the most potent activator of platelets, works by activation of the G protein-coupled protease activated? receptors PAR1 and PAR4. These receptors initiate G protein signaling cascades leading to increases in? intracellular calcium and secretion of autocrine activators, promoting platelet aggregation. Direct thrombin inhibitors? such as bivalirudin are rapidly increasing in use in interventional cardiology. However, thrombin's direct role in? coagulation, as well as its underappreciated protective role on the vasculature through the thrombin/thrombomodulin? activation of Protein C, are blocked by this strategy. An alternate therapeutic target is the PAR receptor system,? because selective blockade of thrombin's cellular signaling effects might further decrease bleeding risk. We have? preliminary evidence that points to differential signaling through PAR4 compared to PAR1; the molecular signaling? process through PAR4 receptors to inside-out integrin signaling, secretion and aggregation will be thoroughly? investigated in Aim 1.
In Aim 2, we will determine the molecular basis of PAR4 signaling with novel G protein? blocking tools designed for studies in human platelets that will inhibit, one at a time, activation of Gq, Gi, Go, G12 or? G13 signaling through PAR receptors.? Although bivalirudin is increasingly used in acute coronary care, the effect of thrombin inhibition on platelet? function has not been thoroughly investigated. Thus we propose two clinical aims to compare platelet PAR? signaling and platelet function.
In Aim 3, we will investigate patients with stable or unstable coronary artery disease.? Their platelet PAR signaling to platelet function will be studied before and during bivalirudin in the Vanderbilt Cardiac? Catheterization Laboratory. The second clinical.
study aims to evaluate PAR signaling in metabolic syndrome and? diabetes, conditions complicated by a high risk of atherothrombotic events.
In Aim 4, we have designed a clinical? study to address the contribution of PAR receptors to the abnormal platelet activation in these thrombotic states.? These detailed mechanistic studies on human platelet PAR1 and PAR4 differential signaling, and studies on effects? of bivalirudin on platelet function will provide insight into platelet activation in atherothrombosis, and has the? potential to impact future antiplatelet therapeutic strategies.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Specialized Center (P50)
Project #
5P50HL081009-02
Application #
7493839
Study Section
Special Emphasis Panel (ZHL1)
Project Start
Project End
Budget Start
2007-03-01
Budget End
2008-02-29
Support Year
2
Fiscal Year
2007
Total Cost
$411,430
Indirect Cost
Name
Vanderbilt University Medical Center
Department
Type
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37212
Boutaud, Olivier; Sosa, I Romina; Amin, Taneem et al. (2016) Inhibition of the Biosynthesis of Prostaglandin E2 By Low-Dose Aspirin: Implications for Adenocarcinoma Metastasis. Cancer Prev Res (Phila) 9:855-865
Wong, L H; Elaine, Huang; Kong, R T (2016) Racial Differences Affecting Night Time Blood Pressure Dipping Groups in Hypertensive Patients. J Hypertens (Los Angel) 5:
Joy, Nino G; Perkins, Jennifer M; Mikeladze, Maia et al. (2016) Comparative effects of acute hypoglycemia and hyperglycemia on pro-atherothrombotic biomarkers and endothelial function in non-diabetic humans. J Diabetes Complications 30:1275-81
Hedrington, Maka S; Mikeladze, Maia; Tate, Donna B et al. (2016) Effects of ?-Aminobutyric Acid A Receptor Activation on Counterregulatory Responses to Subsequent Exercise in Individuals With Type 1 Diabetes. Diabetes 65:2754-9
Joy, Nino G; Mikeladze, Maia; Younk, Lisa M et al. (2016) Effects of equivalent sympathetic activation during hypoglycemia on endothelial function and pro-atherothrombotic balance in healthy individuals and obese standard treated type 2 diabetes. Metabolism 65:1695-1705
Friedman, Eitan A; Texeira, Luisa; Delaney, Jessica et al. (2016) Evaluation of the F2R IVS-14A/T PAR1 polymorphism with subsequent cardiovascular events and bleeding in patients who have undergone percutaneous coronary intervention. J Thromb Thrombolysis 41:656-62
Zagol-Ikapite, Irene; Sosa, Iberia R; Oram, Denise et al. (2015) Modification of platelet proteins by malondialdehyde: prevention by dicarbonyl scavengers. J Lipid Res 56:2196-205
Hedrington, Maka S; Tate, Donna B; Younk, Lisa M et al. (2015) Effects of Antecedent GABA A Receptor Activation on Counterregulatory Responses to Exercise in Healthy Man. Diabetes 64:3253-61
Joy, Nino G; Tate, Donna B; Younk, Lisa M et al. (2015) Effects of Acute and Antecedent Hypoglycemia on Endothelial Function and Markers of Atherothrombotic Balance in Healthy Humans. Diabetes 64:2571-80
Perkins, Jennifer M; Joy, Nino G; Tate, Donna B et al. (2015) Acute effects of hyperinsulinemia and hyperglycemia on vascular inflammatory biomarkers and endothelial function in overweight and obese humans. Am J Physiol Endocrinol Metab 309:E168-76

Showing the most recent 10 out of 48 publications